Zoledronic acid as adjunct to androgen deprivation therapy reduces bone loss in men with prostate cancer

被引：0
|
作者：
不详
机构：
来源：
EUROPEAN UROLOGY SUPPLEMENTS | 2006年 / 5卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：57 / 57
页数：1
相关论文
共 50 条
  • [1] Zoledronic acid to prevent bone loss in Chinese men receiving androgen deprivation therapy for prostate cancer
    Yee, Chi-hang
    Ng, Chi-fai
    Wong, Annie Y. F.
    Chan, Chi-kowk
    Hou, See-ming
    Yip, Sidney K. H.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2011, 7 (02) : 168 - 173
  • [2] Evaluation of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for prostate cancer in Chinese population
    Yee, C. H.
    Ng, C. F.
    Wong, Y. F. A.
    Chan, C. K.
    Hou, S. M.
    Yip, K. H.
    INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 : A202 - A203
  • [3] Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
    Smith, MR
    Eastham, J
    Gleason, DM
    Shasha, D
    Tchekmedyian, S
    Zinner, N
    JOURNAL OF UROLOGY, 2003, 169 (06): : 2008 - 2012
  • [4] Re: Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer
    Pitts, WR
    JOURNAL OF UROLOGY, 2003, 170 (06): : 2392 - 2393
  • [5] Zoledronic acid reduces bone loss in men with prostate cancer receiving goserelin
    Casey, R
    Love, W
    Mendoza, C
    Reymond, D
    Zarenda, M
    BONE, 2006, 38 (03) : S71 - S71
  • [6] PROSTATE CANCER Androgen deprivation therapy and bone loss
    Amir, Eitan
    Tannock, Ian F.
    NATURE REVIEWS UROLOGY, 2009, 6 (12) : 642 - 644
  • [7] Frequency of zoledronic acid to prevent further bone loss in osteoporotic patients undergoing androgen deprivation therapy for prostate cancer
    Wadhwa, Vivek K.
    Weston, Robin
    Parr, Nigel J.
    BJU INTERNATIONAL, 2010, 105 (08) : 1082 - 1088
  • [8] Frequency of zoledronic acid to prevent bone loss in osteoporotic patients requiring androgen-deprivation therapy for prostate cancer
    Wadhwa, V. K.
    Weston, R.
    Parr, N. J.
    BJU INTERNATIONAL, 2007, 99 : 37 - 37
  • [9] Androgen deprivation causes bone loss and increased prostate cancer metastases to bone: Prevention by zoledronic acid.
    Padalecki, SS
    Carreon, MR
    Grubbs, B
    Cui, Y
    Guise, TA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S310 - S310
  • [10] Alendronate prevents bone loss in men on androgen deprivation therapy for prostate cancer.
    Greenspan, SL
    Wagner, JM
    Nelson, JB
    Resnick, NM
    Parker, RA
    JOURNAL OF BONE AND MINERAL RESEARCH, 2005, 20 (09) : S93 - S93
12345